Will Adlai Be The First To Deliver A PI3K Inhibitor For Head And Neck Squamous Cell Carcinoma?
Adlai Nortye (ANL) is developing Buparlisib, a PI3K inhibitor for recurrent/metastatic HNSCC post-anti-PD(L)1 treatment, with a phase III trial (BURAN) underway. Expected OS data in Q1 2025. ANL also has two other clinical drugs, AN4005 and AN0025, and a cash position of $98M as of June 2024.
Adlai Nortye starts subject dosing in Phase II rectal cancer trial
The article discusses the importance of SSR (Server-Side Rendering) in modern web development, emphasizing its role in improving performance and user experience.
© Copyright 2025. All Rights Reserved by MedPath